Skip to main content

Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · IEX Real-Time Price · USD
13.68 0.46 (3.48%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap837.59M
Revenue (ttm)6.84M
Net Income (ttm)-81.23M
Shares Out61.23M
EPS (ttm)-1.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume299,057
Open13.30
Previous Close13.22
Day's Range13.13 - 13.71
52-Week Range3.48 - 30.38
Beta0.46
AnalystsStrong Buy
Price Target34.80 (+154.4%)
Earnings DateNov 3, 2021

About ACRS

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and...

IndustryPharmaceuticals
IPO DateOct 7, 2015
CEONeal Walker
Employees57
Stock ExchangeNASDAQ
Ticker SymbolACRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price forecast is 34.80, which is an increase of 154.39% from the latest price.

Price Target
$34.80
(154.39% upside)
Analyst Consensus: Strong Buy

News

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Tr...

WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

5 days ago - GlobeNewsWire

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

Investigational New Drug Application for ATI-2138 Allowed

2 weeks ago - GlobeNewsWire

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

1 month ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

1 month ago - GlobeNewsWire

Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

3 months ago - GlobeNewsWire

Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?

Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

4 months ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Aclaris Announces Pricing of Public Offering of Common Stock

WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...

5 months ago - GlobeNewsWire

Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate

Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.

5 months ago - Zacks Investment Research

Aclaris Announces Proposed Public Offering of Common Stock

WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

6 months ago - GlobeNewsWire

Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure

Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy endpoint...

6 months ago - Benzinga

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...

6 months ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -111.11% and 20.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., May 07, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...

7 months ago - GlobeNewsWire

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

9 months ago - GlobeNewsWire

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

10 months ago - Zacks Investment Research

Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Investors are excited about the biotech's clinical trial results.

10 months ago - The Motley Fool

ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today

Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today ap...

10 months ago - InvestorPlace

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other symbols:CYADGRTSMRUSNERVTENX
10 months ago - Benzinga

Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options

Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...

11 months ago - GlobeNewsWire